Es wird eine Übersicht über die Ergebnisse der Chemotherapie des fortgeschrittenen Ovarialkarzinoms gegeben. Aus ihr ergeben sich folgende Schlüsse: Die Stadien la und lb sollen bei niedrigem Malignitätsgrad nicht nachbehandelt werden. Bei den Stadien II und I mit hohem Malignitätsgrad kommt eine Abdomenganzbestrahlung in Frage. Der Wert einer intensiven Chemotherapie wird geprüft. Das Stadium II mit Tumorrest sollte vier bis sechs Monate mit einer Cis-Platin-Kombination therapiert werden. Für das Stadium III mit Tumorrest empfíehlt sich eine intensive Chemotherapie, gefolgt von einer Second-look-Operation und einer Abdomenganzbestrahlung. Für Fälle mit großem Resttumor ist die Prognose so ungünstig, daß der Wert einer radikalen Therapie geprüft werden muß.

Keywords:
Ovarialkarzinom, Chemotherapie, Primärtherapie, Prognosefaktoren
This content is only available via PDF.
© 1985 S. Karger AG, Basel
1985
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.